NOVAVAX (NVAX)
$7.46
0.14 (1.88%)
NVAX Stock Quote Delayed 30 Minutes
Novavax Could Be the Biggest Bargain in the Market Right Now
If Novavax gets finally its Emergency Use Authorization next month from the FDA, then you can expect NVAX stock to skyrocket.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$7.17
Market Cap
1.17B
PE Ratio
-3.76
EPS
-1.9818
Volume (Avg. Vol.)
3.86M
Day's Range
$7.17 - $7.42
52-Week Range
$3.81 - $23.86
Dividend & Yield
N/A (N/A)
NVAX Stock Predictions, Articles, and NOVAVAX News
Novavax Is Fighting a Losing Battle on Two Fronts
Novavax could be losing ground in the vaccine war because it’s fighting a battle on two fronts. This isn’t helping NVAX stock move higher.
Worldwide Adoption of Novavax Vaccines Makes It a Winner
Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.
Novavax Stock is in a Tough Spot, but its Fortunes Could Improve
Once the vaccine maker starts booking big sales internationally, NVAX stock could make a trip back to much higher prices.
Novavax Is Oversold, Time To Buy for Future Growth
NVAX stock seems oversold. Focus on low-income countries is likely to deliver revenue and cash flows from covid-19 vaccine sales in 2022.
Novavax Is Worth 77% More Over the Next 2 Years
When comparing its value to competitor Moderna, NVAX stock can reach $164 by 2024 using probability assessments to adjust for risk.
Novavax Stock May Not Be This Cheap For Long
Novavax is expecting approvals from several countries in the coming months and this will take the revenue higher. Buy NVAX stock in the dip.
Novavax Still Has Not Received an FDA EUA as the Market Waits
Novavax still has not received EUA from the FDA as the market waits for approval. NVAX stock looks like a good buy here, especially if analysts' revenue forecasts for 2022 come to pass as forecast.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Happy Friday, trader! We're starting off the day right with an overview of the biggest pre-market stock movers for today!
Here Are a Couple Billion Reasons to Hold Novavax Stock
NVAX stock just came down to an attractive price, and the future looks bright as Novavax continues its expansion into international markets.
NVAX Stock: One Big Reason Novavax Is Stumbling Today
Today, some commentary from Novavax's CEO has investors in NVAX stock re-thinking the bull thesis behind this Covid-19 vaccine play.
Novavax Stock Bulls Face an Uphill Challenge
Off and on the price chart, Novavax investors need to be concerned with a mischievous Wall Street bearishly pricing in the news in NVAX stock.
Novavax Stock Still Has A Solid Chance
Novavax has a lot to look forward to with a surge in Covid-19 cases and a consistent rise in the demand for boosters. Buy NVAX stock.
Dear NVAX Stock Fans, You Should Be Watching This Vaccine News
Novavax has filed for an EUA to distribute Covavax in South Africa. Here's why NVAX stock is rising and could shoot up even higher.
Novavax Remains a Worthwhile Vaccine Play
With its vaccine candidate still in the running, if you can handle its high volatility, you may want to buy NVAX stock after its latest slide.
Don’t Read Too Much into Novavax’s Recent Pullback
Still a vaccine play with high potential, consider NVAX stock a buy at today's prices.
Some Investors Should Buy Novavax Stock on the Dip
Novavax remains poised to sell its coronavirus vaccine to many countries around the world, giving NVAX stock a strong revenue stream in 2022.
NVAX Stock Alert: What Is Going on With Novavax Today?
Here's what's driving the price performance in Novavax and NVAX stock right now, as the stock sinks 4% today on a lower-volume day.
Novavax is In Position to Move Upward While Awaiting More Good News
NVAX stock hasn't had and easy run but FDA approval is closer than ever and may come on the heels of WHO approvals
